Skip Navigation


Mother and children in malaria care

On this page you find information about past webinars hosted by the ACT Consortium.



Watch the recordings

  1. Utility and performance of rapid diagnostic tests in areas with low malaria transmission (12 April 2016)
  2. Cost-effectiveness of introducing rapid diagnostic tests for malaria in the private sector (6 April 2016)
  3. Evaluating antimalarial safety (7 October 2014)


3. Evaluating antimalarial safety


View presentation slides




Clinical trials are not suitable to identify rare, potentially serious adverse effects of drugs, or to define their safety in high risk populations.

Artemisinin-based combination therapies (or ACTs) are considered safe, but there are concerns over their potential to cause damage to parts of the brain. There is also a concern about their safety in patients infected with HIV.  

Collating safety data is a challenge in Africa, where most antimalarials are used and more vulnerable populations reside.

The Safety Data Collection Tools for Real-World Reporting developed by the ACT Consortium are the first step to providing more resources for researchers seeking user-friendly methods to evaluate antimalarial safety.